Cardiac dysfunction and mortality in critically ill patients with COVID-19 - a Swedish multicentre observational study.

Holmqvist J, Beck-Friis J, Jensen C, Dalla K, Mårdstam S, Christensen J, Nordén N, Widing H, Rosén-Wetterholm E, Cavefors O, Yilmaz A, Cronhjort M, Redfors B, Oras J

Acta Anaesthesiol Scand - (-) - [2022-02-04; online 2022-02-04]

The prevalence and importance of cardiac dysfunction in critically ill patients with COVID-19 in Sweden is not yet established. The aim of the study was to assess the prevalence of cardiac dysfunction and elevated pulmonary artery pressure (PAP), and its influence on mortality in patients with COVID-19 in intensive care in Sweden. This was a multicentre observational study performed in five intensive care units (ICUs) in Sweden. Patients admitted to participating ICU with COVID-19 were examined with echocardiography within 72 hours from admission and again after four to seven days. Cardiac dysfunction was defined as left ventricular (LV) dysfunction (ejection fraction <50% and/or regional hypokinesia) or right ventricular (RV) dysfunction (defined as TAPSE <17mm or visually assessed moderate/severe RV dysfunction). We included 132 patients, of whom 127 (96%) were intubated. Cardiac dysfunction was found in 42 (32%) patients. Most patients had cardiac dysfunction at the first assessment (n=35) while a few developed cardiac dysfunction later (n=7) and some changed type of dysfunction (n=3). LV dysfunction was found in 21 and RV dysfunction in 19 patients, while 5 patients had combined dysfunction. Elevated PAP was found in 34 patients (26%) and was more common in patients with RV dysfunction. RV dysfunction and elevated PAP were independently associated with an increased risk of death (OR 3.98, p=0.013 and OR 3.88, p=0.007 respectively). Cardiac dysfunction occurs commonly in critically ill patients with COVID-19 in Sweden. RV dysfunction and elevated PAP are associated with an increased risk of death.

Category: Health

Type: Journal article

PubMed 35122232

DOI 10.1111/aas.14039

Crossref 10.1111/aas.14039


Publications 7.1.2